Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Dijon – page 28

807 clinical trials in Dijon, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Dijon at a glance
807
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

807 trials in Dijon

Open in trial search

Fallopian tube cancer+2

Recruiting

Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or Ubamatamab for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Marginal zone lymphoma refractory

Recruiting

Study Comparing Mosunetuzumab and Lenalidomide with Other Treatments for Patients with Relapsed or Refractory Marginal Zone Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Neuroendocrine tumour+1

Recruiting

Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Brain abscess

Recruiting

Study on Oral Antibiotics Moxifloxacin, Linezolid, and Metronidazole for Patients with Bacterial Brain Abscess

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Aalborg University Hospital

Adenocarcinoma of colon

Recruiting

Study on FOLFOX Chemotherapy for Treating Advanced Colon Cancer in Patients Aged 70 and Older

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Fluorouracil
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Staphylococcal bacteraemia

Recruiting

Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Universitair Medisch Centrum Utrecht

Germ cell cancer

Recruiting

Study on Improving Treatment for Young Adults with Poor-Prognosis Non-Seminomatous Germ-Cell Tumors Using Paclitaxel and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Bleomycin Sulfate
  • Sponsor:Institut Gustave Roussy

Malignant lymphoid neoplasm

Recruiting

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Richter's syndrome

Recruiting

Study of Glofitamab with Rituximab or Obinutuzumab and Drug Combination for Untreated Richter's Syndrome Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:The Royal Marsden NHS Foundation Trust

Brain stem glioma

Recruiting

Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Institut Gustave Roussy

Neoplasm

Recruiting

Study of Pemigatinib for Patients with Recurrent or Metastatic Solid Tumors with FGFR Gene Alteration

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib
  • Sponsor:Unicancer

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Dijon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for head and neck cancer, gastric cancer, and multiple types of lung cancer. Research encompasses novel therapeutic approaches and targeted treatments.

  • Head & Neck Squamous Cell Carcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Non-Small Cell Lung Cancer

Several studies are evaluating new combination therapies and immunotherapy approaches for better treatment outcomes.

02 Immunology & Infectious Diseases

Research focusing on immune system responses and vaccine development, with particular emphasis on COVID-19 prevention and treatment strategies. Studies include innovative approaches to boosting immunity.

  • COVID-19 Vaccine Development
  • Immune System Enhancement
  • Preventive Medicine

Trials are investigating both intranasal and traditional vaccination methods for optimal immune response.

03 Cardiovascular Medicine

Studies focusing on heart disease management and prevention, including innovative treatments for acute myocardial infarction and heart failure prevention strategies.

  • Acute Myocardial Infarction
  • Heart Failure Prevention
  • Pain Management in Cardiac Conditions

Research includes novel pain management approaches and preventive treatments for cardiac conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.